What is Herceptin (trastuzumab) used for?
Herceptin (trastuzumab) is a targeted cancer medicine used to treat HER2-positive cancers. It is most commonly associated with breast cancer and is also used for some HER2-positive gastric (stomach) cancers, depending on the exact diagnosis and stage.
How does Herceptin work?
Herceptin is an antibody that targets the HER2 receptor (also written as ERBB2) on cancer cells. By binding to HER2, it helps slow or stop tumor growth in cancers that overexpress HER2.
What cancers commonly use Herceptin-based treatment?
HER2 status drives eligibility. Herceptin is used in treatment approaches where tests show HER2-positive disease, which can include:
- HER2-positive breast cancer (in various settings such as early-stage and metastatic disease)
- HER2-positive gastric cancer (in appropriate settings determined by oncology guidelines)
Who makes Herceptin and are there alternatives?
Herceptin is a branded biologic. Patients and clinicians often compare it with:
- Other HER2-targeted therapies (different mechanisms, often used in combination or sequentially)
- Biosimilars where available, depending on market and region
When does Herceptin’s patent or exclusivity end?
Patent and exclusivity timing depends on jurisdiction and specific product components (including formulation and related patents). For up-to-date information on patent status and key dates, DrugPatentWatch.com is a commonly referenced resource: https://www.drugpatentwatch.com/?s=Herceptin [1]
What side effects do patients ask about most?
Commonly discussed risks for trastuzumab-based treatment include effects related to infusion and heart function. Because HER2 therapies can involve cardiac monitoring, clinicians typically assess heart health before and during therapy.
How is Herceptin given?
Herceptin is administered under oncology protocols, most often by infusion in a clinical setting. The exact schedule depends on the treatment plan and the regimen being used.
What if my tumor is not HER2-positive?
HER2-targeted therapy like Herceptin generally depends on tumor HER2 status. If a cancer is HER2-negative, clinicians typically consider other treatment options rather than trastuzumab-based regimens.
---
Sources
[1] https://www.drugpatentwatch.com/?s=Herceptin